Foreman, Brandon http://orcid.org/0000-0002-5418-674X
Lee, Hyunjo
Mizrahi, Moshe A.
Hartings, Jed A.
Ngwenya, Laura B.
Privitera, Michael
Tortella, Frank C.
Zhang, Nanhua
Kramer, Joel H.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (K23NS101123)
National Center for Advancing Translational Sciences (UL1TR001425)
Article History
Received: 24 November 2020
Accepted: 27 April 2021
First Online: 7 July 2021
Conflicts of interest
: The INTREPID<sup>2566</sup> trial was supported in part by grants from the U.S. Army Medical Research and Materiel Command (FT) and by Neuren Pharmaceuticals Limited. B. Foreman received research support through the NIH/NINDS. He also receives research funding through the DOD and NSF and speaking fees from UCH Pharma, Inc. M. Privitera received research funds through Neuren Pharmaceuticals Ltd for directing the Core EEG as part of the INTREPID<sup>2566</sup> trial. He also receives grant support from GW/Greenwich and YK, performs EEG interpretation for Sage, Inc. and serves on the DSMB for Astrellas. F.C. Tortella served as principal investigator for the INTREPID<sup>2566</sup> trial and received funding through the DOD and Neuren Pharmaceuticals Limited. The remaining authors report no relevant conflicts of interest.